Company
Pfizer
New York pharmaceutical company; acquired Tukysa's originator Seagen in December 2023 and markets the drug through that subsidiary, alongside Enhertu-competitor Elrexfio and the rest of its oncology portfolio.
2 stories
Regulatory News has published 2 stories about Pfizer between 12 October 2026 and 29 October 2026, each sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 29 October 2026.
This page is generated from Regulatory News’ editorial coverage of Pfizer. It is not an advertisement.
